Twenty-eight nerve-repair implants. Two organ tissues. One printer, 400 kilometres above the planet, with no gravity to fight.
Auxilium Biotechnologies, a clinical-stage company, has done something no lab on Earth has managed: it bioprinted living kidney and liver tissue in orbit. The runs happened aboard the International Space Station (ISS) on Mission AXLM-3, riding NASA's SpaceX CRS-34 cargo flight. The samples splashed down off the California coast on 17 June 2026.
The near-term prize is not transplant organs but better organoids: lab-grown tissue models for drug testing, as regulators push to cut animal use.
The real bet is infrastructure: biomanufacturing as a permanent capability on the commercial stations replacing the ISS.
Gravity is the constraint biology keeps hitting
On the ground, a bioprinted construct fights physics from the first layer. Cells settle. Densities stratify. The fine vascular channels that decide whether a tissue survives past a few millimetres distort under their own weight. Researchers have spent years building scaffolding and perfusion systems to fake what microgravity simply removes.
In orbit, cells distribute themselves evenly. Anthony Atala, director of the Wake Forest Institute for Regenerative Medicine (WFIRM), which supplied the cell lines and tissue designs for the Auxilium run, called the uniform cell distribution achieved on the station evidence of "real possibilities for manufacturing medical devices and tissues in space."
Successfully bioprinting living liver and kidney tissue aboard the International Space Station marks an important step forward for regenerative medicine.— Anthony Atala, MD, Professor and Director, Wake Forest Institute for Regenerative Medicine
One platform, three tissue types in a single flight
The AXLM-3 mission produced kidney, liver and cartilage tissue alongside 28 nerve-repair implants. That is the first time three distinct tissue types have been manufactured during a single spaceflight, and the first time a single manufacturing platform has produced both living tissue and implantable medical devices on the same run.
First multi-product biomanufacturing in orbit
Kidney, liver and cartilage tissue plus 28 nerve-repair implants from one AMP-1 run on AXLM-3. · Auxilium Biotechnologies, 2026
AMP-1 did not arrive here overnight. In November 2024 it printed perfusable blood vessels, walls about the width of a human hair, in under an hour, a feat Auxilium says is not possible on Earth in that time. In 2025 it printed eight medical devices in two hours. The latest mission folds tissues and devices into one flight. The trajectory runs from demo, to throughput, to a platform.
What this is for, and what it is not
The printed kidney is not heading into an operating theatre. Threading a working blood supply through thick human tissue remains unsolved, and a tissue sample is a long way from an organ a patient can receive. Anyone promising orbital transplant kidneys soon is selling a timeline the biology does not support.
The nearer payoff is quieter and more valuable: organoids. These miniature, lab-grown tissue models mimic how a real organ behaves, and drug companies use them to test whether a compound works or turns toxic without a human or an animal. US regulators are actively pushing to cut animal testing, and organoids sit high on the list of named alternatives. Today those models are built on Earth and shipped up; building them in orbit, on demand, removes the launch-schedule dependency.
The vascularization wall
Orbital bioprinting is one front in a wider move to treat biology as space infrastructure. As we wrote in our August piece on Bio-ISRU, engineered microbes are already being pitched to turn space resources into fuel, food and plastic: the same thesis, different organisms. The throughline is that some production is simply easier, or only possible, off Earth.
The post-ISS business case
The ISS is scheduled to retire around 2031. A wave of commercial stations is lining up to replace it, and Auxilium is positioning its hardware for that handoff. The company has a partnership with Starlab Space, announced in February 2026, and works with Vast, another station builder. BioServe Space Technologies, Space Tango and NASA's InSPA program supported the AXLM-3 flight.
Starlab's design matters to the economics: a single-launch, no-assembly-required station that reaches full certification and operation within weeks, not years. For a payload customer running tissue prints, that shortens the gap between an experiment and a repeatable production run. Auxilium's pitch is to turn AMP-1 from a demonstration unit into a standing biomanufacturing facility in orbit, selling access to researchers and device makers rather than shipping one-off results.
What happens to orbital biomanufacturing by 2030?
Probability: 55%. The hardware milestone is real; the station delivery timeline is the variable.
✅ Arguments for
Confirmation criteria: a published price list for orbital organoid runs and a second payload customer beyond Auxilium by 2028.
❌ Arguments against
Disconfirmation criteria: ISS retirement slips past 2033 with no commercial station at scale, or Auxilium fails to publish function metrics.
Development scenarios
🟢 Optimistic scenario (25%)
Implications: orbital biomanufacturing becomes a line item in drug-development budgets, not a research curiosity.
🟡 Base-case scenario (55%)
Implications: steady progress, no breakout, but a durable capability rather than a dead end.
🔴 Pessimistic scenario (20%)
Implications: Auxilium remains a compelling science story with a weak commercial moat.
Peer-reviewed function metrics from the AXLM-3 tissues, the data pharma buyers need.
First paid orbital bioprinting contract on a commercial station (Vast or Starlab).
FDA or EMA guidance expanding organoid use in pre-clinical testing.
A competitor platform (Redwire, Brinter, or a WFIRM spinout) reaching orbit.
